NorthWest Biotherapeutics Inc (NWBO)

[756316]

Q: What's the likelihood that NWBO is actually honesty naked-shorted to a very high degree?
A: Short answer: possible in small pockets, but highly unlikely at the extreme levels often claimed.
Here’s the grounded breakdown:
1. What “high degree naked shorting” would imply


For NWBO to be heavily naked shorted, you would expect clear structural signals:
Persistent fails-to-deliver (FTDs) at elevated levels
Very high borrow fees and difficulty locating shares
Mismatch between reported float and actual tradable shares
Settlement issues or regulatory attention

These are measurable. Extreme naked shorting should show up somewhere.

---
2. What we actually see with NWBO


a) OTC trading environmentNWBO trades OTC, not on a major exchange.
Implications:
Less transparency
More market maker flexibility
More unusual prints and order book behavior

This can look like manipulation, but it is not proof of naked shorting.

---
b) Liquidity profileNWBO shows:
Thin order books
Spread volatility
Market makers stepping in and out (e.g. CDEL, ETRF)

This is typical for:
Low institutional ownership
Speculative biotech trading

Not evidence of systemic naked shorting.

---
c) Dilution overhang (key factor)NWBO has:
Ongoing capital raises
Large authorized share capacity
Historical use of warrants/financing structures

This creates continuous selling pressure and new supply.
Important point:This can mimic the effect people attribute to “synthetic shares.”

---
d) Short interest vs narrativeReported short interest has never shown extreme levels like meme stocks.
If massive naked shorting existed, you would expect:
escalating FTD cycles
regulatory flags

That has not clearly happened.

---
3. Where naked shorting could exist


There are realistic limited cases:
Market makers shorting temporarily without borrow (legal under exemptions)
Settlement timing mismatches
Shorting against expected dilution

This is typically:
short-term
tactical

Not a massive hidden position.

---
4. Why the narrative persists


Main drivers:
Frustration with price vs expectations
Long biotech timelines and uncertainty
OTC opacity
Echo chambers amplifying the idea

It is easier to blame manipulation than to factor in dilution, risk, and timing.

---
5. Reality check


Historically:
Large-scale naked shorting cases are rare
Most claims end up being:
misunderstanding of settlement mechanics
dilution effects
or normal short selling



---
6. Conclusion


NWBO’s price action is more consistently explained by:
dilution and capital needs
binary regulatory outcome
retail-heavy ownership structure

Naked shorting is not required to explain the behavior.

---
Bottom line:
Some level of naked shorting: possible
Extreme, massive hidden shorting: unlikely